Engineering the Future of Drug Development.
One AI platform built from the inside out — purpose-designed for the most complex, regulated, and failure-prone phases of the drug development lifecycle.
9 Out of 10 Drugs Never Reach Patients.
Manufacturing and compliance failures kill programs at clinical stage — and haunt them at commercial scale. This is not a science problem. It is a solvable systems problem. The data is unambiguous: the majority of failures trace directly to Chemistry, Manufacturing, and Controls (CMC) gaps — not to flawed molecules or bad biology.
90%+
IND Holds
Trace directly to CMC failures — not bad science (FDA data)
74%+
FDA Enforcement Actions
Cite operator error at commercial stage (PwC analysis)
$2.6B
Average Cost to Market
Most of it is avoidable manufacturing and compliance spend (Tufts CSDD, 2022)
The Cost of Doing Nothing
Without BioXceed, these are not just risks — they are preventable, high-cost, recurring events that erode timelines, capital, and competitive position at every stage of development.
$1M+ Per Batch Failure
Materials. Labor. Investigation. Without BioXceed: detected after the batch is already lost. With BioXceed: flagged before the failure occurs — keeping product, time, and capital intact.
$3M–$24M Per IND Hold
6–12 months of regulatory consequences. Without BioXceed: CMC gaps discovered at filing. With BioXceed: risks flagged months before IND submission — preserving program timelines.
$50M–$500M Per CRL
$500K–$2M/month burn multiplied by delay. Without BioXceed: compliant on paper, vulnerable in practice. With BioXceed: continuously monitored, auditable, and defensible at every inspection.
The Window Is Open Right Now — and the Data Already Exists
Four forces converged in 2025 to create a once-in-a-decade opportunity. The regulatory framework is being written now. The capital is deploying now. The AI infrastructure cost has dropped to startup-viable.
1
Jan 2025 — FDA Enabled AI in Manufacturing
First-ever draft guidance on AI in regulatory decision-making. Early movers shape the compliance framework being written right now.
2
$370B+ US Biomanufacturing Supercycle
Announced US pharma manufacturing investments over 5 years. Every new facility needs cGMP design intelligence from day one.
3
5–10× Domain AI Outperforms General LLMs
Purpose-built AI beats general models on specialized tasks. Infrastructure cost dropped to startup-viable in 2024.
4
The Training Data Already Exists
Every cGMP process and facility has years of batch records, process data, and compliance documentation — required by regulation, now unlocked by AI.
Why Generic AI Cannot Go Where BioXceed Goes
This is not a close comparison. General-purpose AI — ChatGPT, Grok, Gemini — is structurally unfit for regulated drug manufacturing. Hallucination in a batch record triggers FDA action. A missing audit trail fails Part 11. No generic model can bridge that gap.
The BioXceed Platform
Two modules. One shared data layer. The only AI platform covering the full drug development lifecycle — from Process Development through Commercial Manufacturing. Each module is purpose-built, yet deeply integrated, so intelligence compounds across every stage of your program.
BioXceed Engineering
AI-Powered Facility & Process Design
- Replaces A&E firms for ground-up and existing facility design
- 6–12 months of lead time compressed to days
- Multiple design options with trade-off analysis
- Feasibility and capacity studies on demand, 24/7
- Covers: facility design · utilities · P&ID generation · cGMP readiness · process scalability
BioXceed Intelligence
AI-Powered CMC Compliance & Manufacturing Intelligence
- Operates upstream and alongside your QMS — never touches validated systems
- Predicts failures before they become deviations
- AI companion for PD scientists from day one
- Covers: PD Companion · CMC risk intelligence · CMC compliance · Predictive facility and asset intelligence · MSAT · Scale-up · virtual facility and monitoring